| Major clinical outcomes in antiretroviral therapy (ART)–naive participants and in those not receiving ART at baseline in the SMART study Strategies for Management of Antiretroviral Therapy (SMART) Study Group The Journal of infectious diseases 197 (8), 1133-1144, 2008 | 577 | 2008 |
| Inferior Clinical Outcome of the CD4+ Cell Count–Guided Antiretroviral Treatment Interruption Strategy in the SMART Study: Role of CD4+ Cell Counts and HIV … Strategies for Management of Antiretroviral Therapy (SMART) Study Group The Journal of infectious diseases 197 (8), 1145-1155, 2008 | 259 | 2008 |
| Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection PM Girard, R Landman, C Gaudebout, R Olivares, AG Saimot, P Jelazko, ... New England Journal of Medicine 328 (21), 1514-1520, 1993 | 231 | 1993 |
| Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos (t) ide reverse … JR Arribas, PM Girard, R Landman, J Pich, J Mallolas, ... The Lancet Infectious Diseases 15 (7), 785-792, 2015 | 194 | 2015 |
| Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial SMART Study Group* Annals of internal medicine 149 (5), 289-299, 2008 | 167 | 2008 |
| Prevention of Pneumocystis carinii pneumonia relapse by pentamidine aerosol in zidovudine-treated AIDS patients PM Girard, C Gaudebout, P Lottin, PD Truchis, F Camus, C Marche, ... The Lancet 333 (8651), 1348-1353, 1989 | 124 | 1989 |
| Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal R Landman, R Schiemann, S Thiam, M Vray, A Canestri, S Mboup, ... Aids 17 (7), 1017-1022, 2003 | 118 | 2003 |
| Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta D Roulot, S Brichler, R Layese, Z BenAbdesselam, F Zoulim, V Thibault, ... Journal of Hepatology 73 (5), 1046-1062, 2020 | 113 | 2020 |
| Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL) V Joly, C Burdet, R Landman, M Vigan, C Charpentier, C Katlama, ... Journal of Antimicrobial Chemotherapy 74 (3), 739-745, 2019 | 98 | 2019 |
| Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in HIV-infected patients F Becher, R Landman, S Mboup, CNT Kane, A Canestri, F Liegeois, ... Aids 18 (2), 181-187, 2004 | 90 | 2004 |
| Low genetic barrier to resistance is a possible cause of early virologic failures in once-daily regimen of abacavir, lamivudine, and tenofovir: the Tonus study R Landman, G Peytavin, D Descamps, F Brun Vezinet, H Benech, ... 11th Conference on Retroviruses and Opportunistic Infections, 8-11, 2004 | 87 | 2004 |
| Changes in blood CD8+ lymphocyte activation status and plasma HIV RNA levels during antiretroviral therapy F Bouscarat, M Levacher, R Landman, M Muffat-Joly, PM Girard, ... Aids 12 (11), 1267-1273, 1998 | 80 | 1998 |
| Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients S Fourati, C Charpentier, C Amiel, L Morand-Joubert, S Reigadas, ... Journal of Antimicrobial Chemotherapy 70 (5), 1507-1512, 2015 | 77 | 2015 |
| Quality of life and depression among HIV‐infected patients receiving efavirenz‐or protease inhibitor‐based therapy in Senegal M Poupard, NF Ngom Gueye, D Thiam, B Ndiaye, PM Girard, E Delaporte, ... HIV medicine 8 (2), 92-95, 2007 | 71 | 2007 |
| Prevalence of and factors associated with depression among people living with HIV in France P Feuillet, F Lert, L Tron, C Aubriere, B Spire, R Dray‐Spira, ... HIV medicine 18 (6), 383-394, 2017 | 64 | 2017 |
| Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study. P Gantner, L Cuzin, C Allavena, A Cabie, P Pugliese, MA Valantin, ... HIV medicine 18 (9), 704-708, 2017 | 59 | 2017 |
| HIV-1 DNA levels in peripheral blood mononuclear cells and cannabis use are associated with intermittent HIV shedding in semen of men who have sex with men on successful … J Ghosn, M Leruez-Ville, J Blanche, A Delobelle, C Beaudoux, L Mascard, ... Clinical infectious diseases 58 (12), 1763-1770, 2014 | 57 | 2014 |
| Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial JL Meynard, V Bouteloup, R Landman, P Bonnard, V Baillat, A Cabie, ... Journal of antimicrobial chemotherapy 65 (11), 2436-2444, 2010 | 57 | 2010 |
| Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome C Charpentier, R Landman, C Laouénan, V Joly, G Hamet, F Damond, ... Journal of Antimicrobial Chemotherapy 67 (9), 2231-2235, 2012 | 49 | 2012 |
| Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 infection: TONUS study R Landman, D Descamps, G Peytavin, A Trylesinski, C Katlama, ... HIV Clinical Trials 6 (6), 291-301, 2005 | 47 | 2005 |
